Executive Vice President and President, Lilly Bio-Medicines
Bryce Carmine became executive vice president and president, Lilly Bio-Medicines on November 1, 2009. The business unit, which becomes operational on January 1, 2010, hosts Lilly's global marketing organization and has geographic responsibility for several therapeutic areas in the United States, Japan, the European Union, Canada, and Australia / New Zealand. Carmine is also an executive vice president for Eli Lilly and Company. Since April 2008, he had been executive vice president, global marketing and sales. He is a member of the company’s executive committee and operation’s committee.
Born in New Zealand, he received a bachelor of science in biochemistry from Massey University in 1973. Carmine joined Lilly in 1975 in New Zealand and subsequently held several marketing and management positions in New Zealand before moving in 1983 to corporate headquarters in Indianapolis.
In 1986, he was named general manager of Daewoong-Lilly Pharmaceutical Company in South Korea, a joint venture between Lilly and Daewoong.
He became managing director of Lilly operations in Australia in 1989. During his tenure in Australia, he was actively involved in the Australian Pharmaceutical Research and Manufacturers Association, holding the position of chairman from 1992 to 1995. Carmine then served as the president and general manager of Eli Lilly Japan from 1995 to June 1999 before returning to Indianapolis. Carmine had a series of leadership roles that related to overseeing late-phase development for multiple therapeutic areas, and in March 2005, he was named president, global product development, with responsibility for the development of the late-phase pipeline molecules at Lilly.
